Chloe Ramirez
Jonas Salk was an American virologist and medical researcher who developed one of the world's first successful polio vaccines. After dedicating seven years of his life to developing the vaccine, Salk's inactivated polio vaccine came into use in 1955, and he was immediately hailed as a miracle worker. By 1962, two years after the vaccine was widely available, the average number of polio cases in the U.S. dropped from over 45,000 to 910.
| Characteristics | Values |
|---|---|
| Name of the scientist who invented the vaccine | Jonas Salk |
| Profession | American virologist and medical researcher |
| Born | October 28, 1914 |
| Died | June 23, 1995 |
| Developed the vaccine in | 1955 |
| First successful polio vaccine | Yes |
| Type of vaccine | Inactivated polio vaccine |
| Vaccine came into use | 1955 |
| Vaccine's safety and effectiveness announced | April 12, 1955 |
| Number of children tested on | One million |
| Age group of children tested on | Six to nine |
| Number of polio cases in the US before the vaccine | More than 45,000 |
| Number of polio cases in the US after the vaccine | 910 by 1962 |
| Country where polio was eliminated first | Czechoslovakia in early 1960 |
| Year polio was eliminated in North America | 1994 |
Explore related products
What You'll Learn
- Jonas Salk's vaccine was safe and effective, announced on April 12, 1955
- Salk's vaccine was composed of killed polio viruses
- Salk's vaccine was not patented, allowing for wide distribution
- Salk's vaccine was tested on 1 million children, aged 6-9, in 1954
- By 1962, polio cases in the US dropped to 910 from 45,000
Jonas Salk's vaccine was safe and effective, announced on April 12, 1955
Jonas Salk developed one of the first successful vaccines for polio, a highly infectious disease that affects the nervous system, often causing paralysis and sometimes death. The vaccine was announced on April 12, 1955, and was deemed safe and effective.
Salk was an American virologist and medical researcher. He began working on a polio vaccine in 1948, and his work was funded by the National Foundation for Infantile Paralysis. Salk believed that a killed polio virus could immunize without the risk of infecting the patient. He tested the vaccine on volunteers, including himself and his family, and they all developed anti-polio antibodies with no negative reactions.
In 1954, national testing began on one million children, who became known as the Polio Pioneers. On April 12, 1955, the results were announced, and the vaccine was deemed safe and effective. The federal government implemented a plan to have the vaccine produced by six licensed pharmaceutical companies and distributed to children across the country. By 1962, the average number of polio cases in the US had dropped from over 45,000 to 910.
Salk did not patent the vaccine or seek any profit from it, preferring it to be distributed as widely as possible. He founded the Salk Institute for Biological Studies in La Jolla, California, in 1963. Salk's vaccine was instrumental in eliminating polio in North America by 1994 and in most countries worldwide soon after.
Vaccines: The Power of Active Immunity
You may want to see also
Explore related products
Salk's vaccine was composed of killed polio viruses
Jonas Salk was an American virologist and medical researcher who developed one of the first successful polio vaccines. In 1947, Salk was appointed director of the Virus Research Laboratory at the University of Pittsburgh School of Medicine. There, he began to develop the techniques that would lead to a vaccine to wipe out paralytic poliomyelitis, the most frightening scourge of the time.
Contrary to the era's prevailing scientific opinion, Salk believed that a vaccine composed of "killed" polio viruses could immunize without the risk of infecting the patient. Salk tested the vaccine on volunteers who had not had polio, including himself, his lab scientist, his wife, and their children. All developed anti-polio antibodies and experienced no negative reactions to the vaccine. In 1954, national testing began on one million children, ages six to nine, who became known as the Polio Pioneers.
On April 12, 1955, the results were announced: the vaccine was safe and effective. In the two years before the vaccine was widely available, the average number of polio cases in the U.S. was more than 45,000. By 1962, that number had dropped to 910. Salk never patented the vaccine or earned any money from his discovery, preferring it to be distributed as widely as possible.
The Salk vaccine, also known as IPV, is an inactivated poliovirus given by injection. It confers IgG-mediated immunity in the bloodstream, which prevents polio infection from progressing to viremia and protects the motor neurons, thus eliminating the risk of bulbar polio and post-polio syndrome. In the United States, the vaccine is administered along with tetanus, diphtheria, and acellular pertussis vaccines (DTaP) and a pediatric dose of hepatitis B vaccine.
Vaccine Coverage: Does Your Insurance Plan Measure Up?
You may want to see also
Explore related products
Salk's vaccine was not patented, allowing for wide distribution
Jonas Salk was an American virologist and medical researcher who developed one of the first successful polio vaccines. Born in New York City, he attended the City College of New York and New York University School of Medicine. In 1947, Salk became a professor at the University of Pittsburgh School of Medicine, where he began a project to determine the number of different types of poliovirus. For the next seven years, he dedicated himself to creating a polio vaccine.
Salk's inactivated polio vaccine was introduced in 1955, and it is included on the World Health Organization's List of Essential Medicines. When asked about the patent for the vaccine, Salk famously replied: "Well, the people, I would say. There is no patent. Could you patent the sun?" He chose not to patent the vaccine or profit from it, instead opting for wide distribution. The vaccine was calculated to be worth $7 billion if it had been patented.
Salk's decision not to patent was influenced by the understanding that the public had already funded the vaccine through their donations, and patenting it for profit would have been unfair. The National Foundation for Infantile Paralysis and the University of Pittsburgh explored patenting the vaccine, but their patent attorney determined that Salk's techniques were not novel enough to meet the requirements for a patent.
Salk's vaccine was a significant milestone in the fight against polio, and within two years of its wide availability, the average number of polio cases in the U.S. dropped drastically from over 45,000. By 1962, the number of cases had plummeted to 910. Salk's decision to forgo patenting his life-saving invention exemplifies his commitment to ensuring equitable access to the vaccine, prioritizing public health over personal financial gain.
Immunizations: Facts and Truths You Need to Know
You may want to see also
Explore related products
Salk's vaccine was tested on 1 million children, aged 6-9, in 1954
In the early 1950s, Jonas Salk, a medical researcher, and virologist, developed a vaccine to prevent poliomyelitis, a highly contagious viral infection that can lead to paralysis and even death. By the time Salk began his work, polio had become a widespread and greatly feared disease in the United States and worldwide, with thousands of new cases being reported each year.
After extensive laboratory research and successful testing on animals, Salk and his team were ready to test the vaccine on humans. In 1954, a large-scale clinical trial was conducted, involving approximately 1 million children aged 6 to 9. This massive trial was unprecedented in medical history and demonstrated the urgency and hope surrounding the potential vaccine. The trial was a double-blind, placebo-controlled study, meaning that neither the children nor the administrators knew who was receiving the actual vaccine and who was receiving a placebo.
The chosen age group was particularly vulnerable to polio, and the trial aimed to assess the vaccine's effectiveness and safety in this high-risk population. The trial was a collaborative effort involving the National Foundation for Infantile Paralysis (now known as the March of Dimes), the US Public Health Service, and various local health departments and school systems.
The results of the trial were announced in 1955 and showed that the vaccine was safe and highly effective, providing up to 90% protection against polio. This announcement brought immense relief and joy to the public and the medical community, offering a glimmer of hope in the fight against this devastating disease. The vaccine was then licensed and quickly put into mass production, with millions of doses administered to children across the United States and other countries.
Pneumonia Vaccine for Seniors: Free or Fee?
You may want to see also
Explore related products
By 1962, polio cases in the US dropped to 910 from 45,000
Jonas Salk developed one of the first successful vaccines for polio, a highly infectious disease that affects the nervous system and can lead to paralysis or even death. In the mid-20th century, the poliovirus was widespread and dangerous, killing or paralysing over half a million people annually. In 1947, Salk began his work on developing a polio vaccine at the University of Pittsburgh School of Medicine. He believed that a vaccine composed of a "'killed' polio virus could immunise without the risk of infecting the patient".
Salk's vaccine was first proven safe and effective in 1954, when national testing began on one million children aged six to nine, who became known as the "Polio Pioneers". On April 12, 1955, the results were announced, and the vaccine was deemed a success. This led to a rapid decline in polio cases in the US, with the average number of cases dropping from over 45,000 in the two years before the vaccine to just 910 cases by 1962.
Salk's commitment to equitable access to his vaccine is notable. He chose not to patent it or profit from it, instead allowing six pharmaceutical companies to produce it and maximising its global distribution. This decision was based on his understanding that elimination efforts would only succeed with universal low-cost or no-cost vaccination. When asked about the patent, Salk famously replied, "Well, the people, I would say. There is no patent. Could you patent the sun?"
By the time an oral polio vaccine developed by Albert Sabin came into commercial use in 1961, replacing Salk's injected vaccine, domestic transmission of polio had already been significantly curbed in the US. In 1963, Salk founded the Salk Institute for Biological Studies in La Jolla, California, which continues to be a centre for medical and scientific research. Polio was eliminated from North America by 1994 and from most countries soon after, although it has not been entirely eradicated globally.
Pneumonia Vaccine: Walking Pneumonia Protection?
You may want to see also
Frequently asked questions
Jonas Salk's inactivated polio vaccine came into use in 1955.
Salk believed that his vaccine, composed of "killed" polio virus, could immunize without the risk of infecting the patient.
No, Salk never patented the vaccine or earned any money from his discovery. He preferred it to be distributed as widely as possible.
Jonas Salk was an American virologist and medical researcher.
Yes, within a year of the vaccine being produced, polio deaths declined by 50%. Polio has now been totally eradicated in most of the world.
